CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.12% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money
0.2596
3.59%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.0056
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023346 %
Charges from full value of position ($-4.44)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.023346%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001124 %
Charges from full value of position ($0.21)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.001124%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 0.2506
Open 0.2596
1-Year Change -91%
Day's Range 0.2531 - 0.2664
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jan 17, 2025 0.2596 0.0230 9.72% 0.2366 0.2684 0.2366
Jan 16, 2025 0.2506 0.0110 4.59% 0.2396 0.2569 0.2396
Jan 15, 2025 0.2468 0.0072 3.01% 0.2396 0.2569 0.2396
Jan 14, 2025 0.2501 0.0104 4.34% 0.2397 0.2605 0.2397
Jan 13, 2025 0.2504 0.0008 0.32% 0.2496 0.2541 0.2346
Jan 10, 2025 0.2645 0.0049 1.89% 0.2596 0.2667 0.2596
Jan 8, 2025 0.2726 -0.0017 -0.62% 0.2743 0.2800 0.2546
Jan 7, 2025 0.2826 0.0030 1.07% 0.2796 0.2896 0.2623
Jan 6, 2025 0.2797 0.0001 0.04% 0.2796 0.2951 0.2796
Jan 3, 2025 0.2754 0.0146 5.60% 0.2608 0.2933 0.2607
Jan 2, 2025 0.2503 0.0076 3.13% 0.2427 0.2796 0.2427
Dec 31, 2024 0.2508 0.0003 0.12% 0.2505 0.2596 0.2337
Dec 30, 2024 0.2471 0.0075 3.13% 0.2396 0.2596 0.2361
Dec 27, 2024 0.2359 -0.0208 -8.10% 0.2567 0.2596 0.2222
Dec 26, 2024 0.2460 0.0264 12.02% 0.2196 0.2531 0.2196
Dec 24, 2024 0.2381 0.0271 12.84% 0.2110 0.2419 0.1997
Dec 23, 2024 0.2132 -0.0201 -8.62% 0.2333 0.2333 0.2118
Dec 20, 2024 0.2290 0.0194 9.26% 0.2096 0.2456 0.1996
Dec 19, 2024 0.2011 -0.0225 -10.06% 0.2236 0.2296 0.1903
Dec 18, 2024 0.2235 -0.0093 -3.99% 0.2328 0.2463 0.2149

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

GlycoMimetics Company profile

About GlycoMimetics Inc

GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovery and development of novel glycomimetic. Its drug candidates include Uproleselan, GMI-1359, Rivipansel, GMI-1687, and Galectin Antagonists. Its Uproleselan a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), a life-threatening hematologic cancer, and potentially other hematologic cancers. The GMI-1359 targets E-selectin and a chemokine receptor. Its Rivipansel is a glycomimetic drug candidate that act as , a pan-selectin antagonist for treatment of vaso-occlusive crisis. It has designed antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. Galectin Antagonists includes Galectin-3, which is a carbohydrate-binding protein.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, GlycoMimetics Inc revenues decreased 89% to $1.2M. Net loss increased 24% to $63.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research & Development Expenses increase of 8% to $45.3M (expense), Interest income decrease of 96% to $20K (income).

Equity composition

Common Stock, $0.001 Par, 100M Auth shares, 17,555,497 issd,. Insiders Owns approx. 10.08%.

Industry: Bio Therapeutic Drugs

9708 Medical Center Drive
ROCKVILLE
MARYLAND 20850
US

People also watch

BTC/USD

104,252.25 Price
+4.290% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

US100

21,441.70 Price
+1.820% 1D Chg, %
Long position overnight fee -0.0233%
Short position overnight fee 0.0011%
Overnight fee time 22:00 (UTC)
Spread 7.0

ETH/USD

3,435.27 Price
+3.830% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

Gold

2,703.08 Price
-0.430% 1D Chg, %
Long position overnight fee 0.0056%
Short position overnight fee -0.0138%
Overnight fee time 22:00 (UTC)
Spread 0.60

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading